



Versartis
Investor Relations Department
4200 Bohannon Drive
Suite 250
Menlo Park, CA 94025
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: VSAR

| | |
|---------------|----------------------------|
| Last Trade: | 16.65 |
| Trade Time: | 4:00 PM ET Aug 16, 2017 |
| Change: | 0.00 (0.000%) |
| Day Range | 16.50 - 17.00 |
| 52-Week Range | 9.05 - 24.00 |
| Volume | 123,555 |

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Versartis, Inc. (NASDAQ: VSAR) is an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone to treat growth hormone deficiency (GHD) in children and adults.

Somavaratan is intended to reduce the injection burden of daily therapy and improve therapeutic outcomes through enhanced adherence and convenience with twice-monthly dosing, a fine gauge needle autoinjector device and room temperature storage.

Versartis is currently evaluating somavaratan for the treatment of pediatric ... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Aug 2, 2017

[Versartis to Present at the Canaccord Genuity Growth Conference](#)

Jul 27, 2017

[Versartis Reports Second Quarter 2017 Financial Results](#)

Jun 1, 2017

[Versartis Appoints Eric Dobmeier to Board of Directors](#)

May 22, 2017

[Versartis Presents 3-Year Somavaratan Safety and Efficacy Data and Pediatric Program Baseline Demographics at the 19th European Congress of Endocrinology](#)

Apr 27, 2017

[Versartis Reports First Quarter 2017 Financial Results](#)

Financials [\[View all \]](#)

[Second Quarter Financial Results](#)

Mar 10, 2017

[Annual Report \(10-K\)](#)

Aug 14, 2017

[Proxy Statement \(DEF 14A\)](#)

Aug 7, 2017

[Quarterly Report \(10-Q\)](#)

May 10, 2017

[Quarterly Report \(10-Q\)](#)

Nov 4, 2016

[Quarterly Report \(10-Q\)](#)